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Summary
We examined whether men with anabolic steroid induced hypogonadism (ASIH) seeking 
testosterone supplementation therapy (TST) regretted their decision to use anabolic androgenic 
steroids (AAS) and what their reasons were for this regret. An anonymous, prospective survey was 
distributed to 382 men seeking follow-up treatment for hypogonadism. Prior AAS use was 
confirmed by self-report and men were categorised based upon whether they regretted (R) or did 
not regret (NR) their use of AAS. The average patient age was 40±0.9 years (n=79) and 15.2% 
expressed regret over AAS use. No demographic differences were identified between those who 
regretted AAS use (n=12) and those who did not (n=67). Regret was not related to ASIH diagnosis 
or to AAS-related side effects like increased aggression, mood disorders, erectile dysfunction, 
acne, fluid retention or dyslipidemia. Those who regretted AAS use were significantly more likely 
to have not comprehended the negative impact on future fertility (p<0.030). Actual fertility issues 
were comparable in men who regretted AAS use (16.7%) and those who did not (13%). A total of 
15.2% of men regretted using AAS. A lack of awareness regarding the negative long-term effects 
on fertility was the primary factor related to regret of AAS use in men with ASIH.
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INTRODUCTION
The isolation of the testosterone molecule has resulted in the development of multiple 
synthetic derivatives. Classified as anabolic-androgenic steroids (AAS), the desirable effects 
of these products included increased muscle mass and strength along with decreased 
recovery times and improved healing (Hough, 1990). Amongst the general population, an 
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estimated 3 million people have reported using AAS (Maravelias et al., 2005). Prior 
exposure to AAS has recently been postulated to contribute to profound hypogonadism 
(serum testosterone <50 ng/ml) as well as anabolic steroid induced hypogonadism (ASIH) 
(Coward et al., 2013). Indeed, a preliminary study in 1990 identified inhibited levels of 
luteinising (LH) and follicle stimulating hormone (FSH) for 1–3 years following last 
documented use of AAS (Jarow & Lipshultz, 1990).
While the duration of gonadotrophin suppression in response to AAS is unknown, it is likely 
related to the types of AAS used as well as the duration (Tan & Scally, 2009). While AAS 
contributes to effective muscle building by diversion of nitrogenic compounds to lean body 
mass (Sjoqvist et al., 2008), not all AAS compounds function equally with regard to the 
ratio of anabolic to androgenic effects (Kicman, 2008). In high doses, all AAS have the 
potential to virilise (Shahidi, 2001) with other, adverse effects being similarly both type- and 
dose-dependent (Landry & Primos, 1990).
Of the numerous AAS side effects known, fluid retention, decreased testicular size, acne, 
aggressiveness and negative effects on sperm counts, cholesterol and hematocrit have been 
noted to be the most common (Coward et al., 2013). Interestingly, the decreased sperm 
counts, motility and altered morphology (Dohle et al., 2003) associated with AAS are 
typically transient, with evidence that semen parameters can spontaneously recover within 
4–12 months after discontinuation (Knuth et al., 1989; Turek et al., 1995). Recovery may be 
delayed due to testicular atrophy and dysfunctional spermatogenesis (Schurmeyer et al., 
1984; Turek et al., 1995; Gazvani et al., 1997; Menon, 2003) along with germ cell apoptosis 
(Moretti et al., 2007; Shokri et al., 2010).
In other studies examining illicit substance use, decisions made in youth and adolescence 
tends to lead to regret later in adult life (Byrnes, 2002). Since usage of these agents (such as 
AAS) may be ascribed to impulsiveness, and given that a person's values can change over 
time leading to regret, it is tempting to speculate that prior AAS use could lead to regret as 
individuals' priorities and values change over time (Igra & Irwin, 1995). Indeed, regret has 
previously been shown to play a role in the decision to alter substance abuse patterns (Blume 
& Schmaling, 1998) and has been associated with less alcohol and marijuana use in young 
adults (Stoddard et al., 2012) suggesting that men with prior AAS use are more likely to 
seek medical assistance for ASIH given their familiarity with the symptoms and long-term 
side effects. Furthermore, previous studies (Sanford, 2012; Van den Broek et al., 2013;) 
have found spousal and partner feelings and anxiety to play a role in regret so we 
hypothesised that regretting AAS use may be associated with a lack of spousal awareness 
that would then impact a couples relationship. We therefore sought to determine whether 
patients presenting with ASIH regretted their decision to use AAS and what factors drove 
this regret.
MATERIALS AND METHODS
After Institutional Review Board (IRB) approval, a self-administered anonymous survey 
was distributed to male patients seeking treatment for hypogonadism in a tertiary, academic 
urology clinic. The survey was self-administered, confidential and anonymous. 
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Hypogonadism was diagnosed with serum total testosterone values combined with patient 
history of hypogonadal symptoms and treatments included injections, gels or pellets with 
modality of TST not considered with regards to responses. Patients seeking treatment for 
infertility were excluded and surveys were also excluded from analysis if they contained 
incomplete or conflicting responses. Follow-up visits for hypogonadism and TST were used 
when administering the survey. Patients undergoing initial consultations were excluded 
since given the anonymous nature of the survey, it was impossible to know whether these 
men were actually hypogonadal and if they were treated or not.
The survey included basic patient demographics such as age, sexual orientation, marital 
status, level of education and income. Those men who self-reported AAS use were asked to 
complete a follow-up second survey. This second portion gathered data that determined 
characteristics of those patients who engaged in AAS use. Regret was determined using a 
question in this second part of the survey that stated “Do you regret using anabolic steroids” 
and could have been answered either Yes or No. In no survey was this question left blank. 
The effect of AAS use on relationship was addressed by the question “Does your spouse/
significant other know about your previous or current steroid use”?. The answer options 
were: (1) Yes – Has not affected relationship, (2) Yes – Has affected relationship, (3) No – 
Has not affected relationship, (4) No – Has affected relationship and, (5) Not applicable. No 
patient selected option 5 as a response. To further assess impact of AAS use the following 
question was asked: When you first decided to use anabolic steroids, did you understand the 
potential long-term effect it could have on your (a) natural testosterone production (Yes/No) 
(b) fertility (Yes/No). A follow up question asked: “Have anabolic steroids affected your: (a) 
Erections (Yes/No), (b) Fertility (Yes/No)”. The majority of the questions produced single-
answer responses via multiple choice or yes/no answers.
Data were analysed using Student's t-test for scalar variables and Fisher's exact test for 
categorical variables. Correlation analysis between variables was performed using 
Spearman's rank correlation, and odds ratios were calculated when appropriate. Analysis 
was performed using Microsoft Excel (Microsoft, Redmond, WA) and GraphPad Prism 6 
software (GraphPad Software Inc.; La Jolla, CA) with a p<0.05 considered statistically 
significant. All values were reported as means±SEM, unless otherwise noted.
RESULTS
Results from an anonymous, prospective survey distributed to hypogonadal men being 
treated with TST at a high-volume academic Urology clinic were assessed. A total of 79 
men stated that they had previously used AAS (Table 1). From these men, 84.8% (n=67) 
stated that they had no regret (NR) while 15.2% (n=12) expressed regret (R) about their 
AAS use (Table 1). A total of 382 surveys were distributed with 20.8% of patients reported 
prior AAS exposure. No statistical differences were identified between mean age (p=0.070), 
height (p=0.450), weight (p=0.620) and BMI (p=0.300). The majority of the men were 
heterosexual and married. Men who regretted use were more likely to have no children 
(58.3%) while men who were not regretful of their prior AAS use were more likely to have 
1–2 children (58.2%). Both groups were educated with a sizable percentage having current 
income levels of >$150,000 (Table 1).
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In order to determine whether side effects from AAS use contributed to an individual's 
regret, we asked men whether they experienced negative impacts on their cholesterol levels 
or noted changes in their aggression, acne and levels of fluid retention (Figure 1A). In each 
case, the differences between men who did and did not have regret were not statistically 
significant, suggesting these side effects did not contribute to their feelings (Figure 1A). 
Since previous studies (Sanford, 2012; Van den Broek et al., 2013) found partner effects and 
anxiety to play a role in regret, we hypothesised that regretting AAS use may be associated 
with a lack of spousal awareness that would then impact a couples relationship (Figure 1B). 
Surprisingly, most partners were aware of the AAS use, and it had no effect on a couple's 
relationship (Figure 1B).
Erectile dysfunction has previously been shown to cause a high source of bother and regret 
for men post-prostatectomy due to shame, embarrassment, and a reduction in general life 
happiness (Nelson et al., 2010). We thus sought to determine whether men regretting AAS 
use had erectile dysfunction and whether it affected their mood. Interestingly, a total of 
40.5% (n=32/79) of men with prior AAS use indicated having erectile dysfunction. A 
similar number of people in those men with R (50%, n=6/12) and those with NR (38.8%, 
n=26/67) experienced erectile dysfunction (p=0.537, Figure 1C). Mood was similarly 
affected (R=41.7%, n=5/12; NR=32.8%, n=22/67).
Lastly, we evaluated whether perception of future long-term effects on testosterone and 
fertility contributed to feelings of regret (Figure 2). Of those men with regret, 25% (n=3/12) 
stated that they did not understand the potential future impact of AAS use on their serum 
testosterone levels (Figure 2A). Compared with the 56.7% of (n=38/67) men who did not 
experience regret, this value approached statistical significance (p=0.06). However, men 
with regret were significantly less likely to have understood the potential long-term, 
negative effects on fertility from AAS use (R=16.6% understood, n=2/12 vs. NR=52.2% 
understood, n=35/67; p=0.029). Interestingly, the amount of men who actually experienced 
fertility difficulties was similar between the subgroups (R=16.7%, n=2/12; NR=13.4%, 
n=9/67)(Figure 2B). This suggests that the perception of future long-term fertility problems 
is more important in regretting AAS use than actual difficulties with conception.
DISCUSSION
AAS use in hypogonadal men seeking TST is common (Coward et al., 2013). Since AAS 
use has been suggested to be addictive, and other addictive substances such as marijuana are 
associated with regret following use, we sought to elucidate whether hypogonadal patients 
with a history of AAS regretted their decision to use AAS and what factors drove these 
feelings (Buckley et al., 1988; Kanayama et al., 2001; Evans, 2004; Parkinson & Evans, 
2006; Cohen et al., 2007). Most men who understood the effects that AAS would have on 
their fertility did not experience regret; however, those who regretted AAS use were 
significantly more likely to not have comprehended the negative impact on fertility. In 
contrast, the rates of actual fertility issues were equal in men who regretted AAS use and 
those who did not.
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Given the illicit nature of AAS, information regarding their usage patterns is difficult to 
identify in the context of the medical literature. The only study to date that has examined 
feelings of regret with regards to AAS use was conducted in 1995; however, it was focused 
on professional athletes who used AAS for competitive reasons (Silvester, 1995). In that 
study by Silvester et al. (1995) from the cohort of 22 competitive shot-put/discus athletes 
studied, only 9.l% (n=2) noted that they regretted their prior AAS use. Furthermore, a total 
of 86% believed there were no long-term physical health problems, with only one patient 
(4.5%) stating that AAS caused a permanent reduction in the size of his testicles (Silvester, 
1995). Indeed, the majority of the patients in the Silvester study (1995) perceived their 
health problems to be a nuisance, rather than a severe or debilitating condition. While the 
population in the current study is different, the frequency at which patients reported regret is 
similar.
When considering the long-term impact of AAS on health, the current study examined 
whether the well-known side-effects of altered cholesterol values and increased levels of 
aggression, acne, and fluid retention were a reason for regret (Figure 1). While no 
differences were found, a possible limitation to our anonymous survey approach was that it 
was not possible to ascertain the exact medical history of our study participants. As such, we 
relied on patient self-report rather than actual medical records. Furthermore, given the 
anonymous nature of the survey, we were unable to ascertain the reliability of the survey or 
to correlate serum levels to patient responses.
Given that AAS users have previously been shown to experience poor parental relationships 
(Skarberg & Engstrom, 2007), and partner/spousal anxiety and depression results in 
emotional distress (Van den Broek et al., 2013), we sought to analyse whether spousal 
awareness and the resultant relationship consequences had any influence on AAS-induced 
regret. In our population, the majority of spouses and partners were aware of their partners 
AAS use; with most mentioning that it had no effect on their relationship (Figure 1). 
Similarly, mood affective disorders have been recognised as a complication of AAS use 
with case reports describing everything from unspecified mood disturbances (Lindstrom et 
al., 1990) as well as hypomania, mania, irritability, and feelings of power and invincibility 
(Rashid et al., 2007). In our study population, spousal communication does not appear to be 
an issue, and while we were unable to capture any psychiatric disorders, mood disturbances 
were similar between men with and without regret.
Unfortunately, since most men begin AAS at a young age and are presumed to obtain the 
medication from illicit sources, they are not educated regarding the possible negative 
outcomes that come with their use. AAS suppress LH and FSH leading to acute 
hypogonadotropic hypogonadism (Coward et al., 2013). In a subset of men, this 
anabolicsteroid induced hypogonadism (ASIH) can result in long-term, or permanent 
inhibition of their hypothalamic-pituitary axis (Jarow & Lipshultz, 1990; Pirola et al., 2010; 
Boregowda et al., 2011). Furthermore, the exogenously elevated serum testosterone levels 
obtained from AAS results in oligospermia and azoospermia (Dohle et al., 2003). A primary 
finding of our study was that regretful prior AAS users did not understand the possibility 
that ASIH could result and future fertility could be hampered (Figure 4). Indeed those men 
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with regret were less likely to have understood the potential negative impacts on both long-
term testosterone levels (p=0.06) and fertility (p=0.029) than men without regret.
The findings in the current study are important when dealing with hypogonadal patients with 
ASIH seeking TST. Since a proportion of patients may be hypogonadal due to ASIH 
(Coward et al., 2013), asking about AAS is important. Furthermore, it is valuable for men 
with ASIH to understand the impact that exogenous AAS may have had on their fertility. In 
these men with a previous history of AAS who present with infertility and hypogonadism, 
multiple pharmacological treatments are available, including exogenous testosterone, human 
chorionic gonadotropin (hCG), human menopausal gonadotropin (hMG), recombinant FSH, 
and clomiphene citrate (Martikainen et al., 1986; Gill, 1998; Menon, 2003; Ioannidou-Kadis 
et al., 2006; Hsieh et al., 2013; Rahnema et al., 2014).
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AAS use and regret. (A) Men who reported regret of AAS use experienced similar side-
effects for cholesterol (p=0.29), aggression (p=1), acne (p=0.34) and fluid retention (p=0.35) 
to those who did not regret AAS use. (B) No differences in regret were found in situations 
where men had spouses who were aware of their use of AAS with no relationship effects 
(Column 1; p=0.44). No statistical differences were found between men who regretted prior 
AAS use and those who did not in the following situations: (Column 2) Spouse was aware 
of AAS use and this had effects on the relationship (Aware & Effect, p=1); (Column 3) 
Spouse was not aware of AAS use and this had no effects on the relationship (Not Aware & 
No Effect, p=1) and; (Column 4) Spouse was not aware and this effected the relationship 
(p=1). (C) Regret had no effect on erections and mood in men who reported AAS use. 
Decreased frequency and quality of erections (p=0.54) as well as poor mood (p=0.74) 
affected men who regretted AAS use to a similar degree as those who did not (Black 
bars=men with regret; white bars=men with NO regret).
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Regret, AAS and the long-term effects on serum testosterone levels and fertility. (A) Men 
who regretted their AAS use (black bars) did not understand the potential long-term effects 
on their serum testosterone levels; however, this relationship did not reach statistical 
significance (p=0.06). Patients who regretted their prior AAS use were less aware of the 
potential long-term effects on future fertility (*, p=0.029) compared to those that did not 
regret AAS use (white bars). (B) Men with regret were equally as likely to experience actual 
problems with fertility as those without regret. These results suggest that patient perceptions 
had more impact on regret than actual events (Black bars=men with regret; white bars=men 
with NO regret).
Kovac et al. Page 10

























Kovac et al. Page 11
Table 1
Comparison of the demographics between patients who either regret their decision to use AAS (n=12) or are 
unaffected (n=68) by prior AAS use. Values within the columns are depicted as mean±SEM with the total 
number of patients for each section shown in brackets.
No Regret of AAS use Regret of AAS use
Percentage of survey respondents who noted previous AAS use (n=79) 84.8% (n=67/79) 15.2% (n=12/79)
Mean Age (Years) 41.1±1.0 (n=67) 36.4±1.9 (n=12)
Height (inches) 70.8±0.3 (n=67) 71.4±0.6 (n=12)
Weight (Lbs) 213.1±3.5 (n=65) 208.3±10.2 (n=12)
Mean BMI (kg/m2) 29.9±0.5 (n=65) 28.7±1.3 (n=12)
Sexual Orientation:
 Heterosexual (n) 98.5% (n=66/67) 100% (n=12)
 Homosexual (n) 1.5% (n=1/67) 0%
Marital Status:
 Single (n) 26.9% (n=18/67) 41.7% (n=5/12)
 Married (n) 55.2% (n=37/67) 41.7% (n=5/12)
 Divorced (n) 10.4% (n=7/67) 16.7% (n=2/12)
 Cohabitating (n) 7.5% (n=5/67) 0%
Number of Children:
 0 35.8% (n=24/67) 58.3% (n=7/12)
 1–2 58.2% (n=39/67) 33.3% (n=4/12)
 3–5 4.5% (n=3/67) 0%
 6 or more 1.5% (n=1/67) 8.3% (n=1/12)
Highest Level of Education:
 Grade School 1.5% (n=1/66) 0%
 High School 13.6% (n=9/66) 0%
 Some College/University 33.3% (n=22/66) 50% (n=6/12)
 College/University 33.3% (n=22/66) 41.7% (n=5/12)
 Graduate Level 18.2% (n=12/66) 8.3% (n=1/12)
Current Income:
 <25,000 6.1% (n=4/66) 9.1% (n=1/11)
 25,000–50,000 1.5% (n=1/66) 9.1% (n=1/11)
 50,001–75,000 24.2% (n=16/66) 36.4% (n=4/11)
 75,001–100,000 18.2% (n=12/66) 9.1% (n=1/11)
 100,001–150,000 21.2% (n=14/66) 0%
 150,001–200,000 13.6% (n=9/66) 27.3% (n=3/11)
 >200,000 15.2% (n=10/66) 9.1% (n=1/11)
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